Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

[Use of health resources and costs associated with the diagnosis and treatment of each episode of deep vein thrombosis and bleeding in patients undergoing orthopaedic surgery for hip or knee].

Sicras-Mainar A, De Salas-Cansado M, Ruiz-Antorán MB, Cuesta-Peredo D, Lizano-Díez I, Betegón-Nicolas L, Navarro-Artieda R.

Rev Esp Cir Ortop Traumatol. 2012 Sep-Oct;56(5):341-53. doi: 10.1016/j.recot.2012.04.003. Epub 2012 Jun 17. Spanish.

PMID:
23594888
2.

In-hospital risk of venous thromboembolism and bleeding and associated costs for patients undergoing total hip or knee arthroplasty.

Vekeman F, LaMori JC, Laliberté F, Nutescu E, Duh MS, Bookhart BK, Schein J, Dea K, Olson WH, Lefebvre P.

J Med Econ. 2012;15(4):644-53. doi: 10.3111/13696998.2012.669438. Epub 2012 Mar 12.

PMID:
22356512
3.

Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.

Haentjens P, De Groote K, Annemans L.

Arch Orthop Trauma Surg. 2004 Oct;124(8):507-17. Epub 2004 Sep 10.

PMID:
15365714
4.

[Total knee and hip prosthesis: variables associated with costs].

Herrera-Espiñeira C, Escobar A, Navarro-Espigares JL, Castillo Jde D, García-Pérez L, Godoy-Montijano A.

Cir Cir. 2013 May-Jun;81(3):207-13. Spanish.

PMID:
23769249
5.

[Benefit/risk ratio analysis from a possible anticoagulation of asymptomatic deep venous thrombosis in major orthopedic surgery].

Barrellier MT, Samama CM.

J Mal Vasc. 2013 May;38(3):178-84. doi: 10.1016/j.jmv.2013.01.002. Epub 2013 Feb 12. Review. French.

PMID:
23415379
6.

Economic consequences of venous thromboembolism following major orthopedic surgery.

Oster G, Ollendorf DA, Vera-Llonch M, Hagiwara M, Berger A, Edelsberg J.

Ann Pharmacother. 2004 Mar;38(3):377-82. Epub 2004 Jan 12.

PMID:
14742829
7.

Frequency of myocardial infarction, pulmonary embolism, deep venous thrombosis, and death following primary hip or knee arthroplasty.

Mantilla CB, Horlocker TT, Schroeder DR, Berry DJ, Brown DL.

Anesthesiology. 2002 May;96(5):1140-6. Erratum in: Anesthesiology 2002 Aug;97(2):531.

PMID:
11981154
8.

Socioeconomic burden of total joint arthroplasty for symptomatic hip and knee osteoarthritis in the Italian population: a 5-year analysis based on hospitalization records.

Piscitelli P, Iolascon G, Di Tanna G, Bizzi E, Chitano G, Argentiero A, Neglia C, Giolli L, Distante A, Gimigliano R, Brandi ML, Migliore A.

Arthritis Care Res (Hoboken). 2012 Sep;64(9):1320-7. doi: 10.1002/acr.21706.

9.

Cost of venous thromboembolism following major orthopedic surgery in hospitalized patients.

Ollendorf DA, Vera-Llonch M, Oster G.

Am J Health Syst Pharm. 2002 Sep 15;59(18):1750-4.

PMID:
12298113
10.

Dalteparin vs. enoxaparin as prophylaxis for deep-vein thrombosis after total hip or knee arthroplasty: a retrospective analysis.

Krotenberg R, Adler U, Pomeranz B, Miller JD, Russell MW.

Am J Phys Med Rehabil. 2001 Dec;80(12):889-95.

PMID:
11821667
11.

Direct hospital cost determinants following hip and knee arthroplasty.

Peel TN, Cheng AC, Liew D, Buising KL, Lisik J, Carroll KA, Choong PF, Dowsey MM.

Arthritis Care Res (Hoboken). 2015 May;67(6):782-90. doi: 10.1002/acr.22523.

12.

Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population.

Vekeman F, LaMori JC, Laliberté F, Nutescu E, Duh MS, Bookhart BK, Schein J, Dea K, Olson WH, Lefebvre P.

J Med Econ. 2011;14(3):324-34. doi: 10.3111/13696998.2011.578698. Epub 2011 Apr 20.

PMID:
21506632
13.

[Cost-effectiveness analysis of apixaban compared to dabigatran in the prevention of venous thromboembolism in patients subjected to total knee or hip replacement].

Gómez-Cerezo JF, Gómez-Arrayás I, Suárez-Fernández C, Betegón-Nicolás L, de Salas-Cansado M, Rubio-Terrés C.

Rev Esp Cir Ortop Traumatol. 2012 Nov-Dec;56(6):459-70. doi: 10.1016/j.recot.2012.07.009. Epub 2012 Sep 7. Spanish.

PMID:
23594943
14.
15.

Impact of postoperative venous thromboembolism on Medicare recipients undergoing total hip replacement or total knee replacement surgery.

Baser O, Supina D, Sengupta N, Wang L, Kwong L.

Am J Health Syst Pharm. 2010 Sep 1;67(17):1438-45. doi: 10.2146/ajhp090572.

PMID:
20720243
16.
17.

Resource utilization and costs before and after total joint arthroplasty.

Bozic KJ, Stacey B, Berger A, Sadosky A, Oster G.

BMC Health Serv Res. 2012 Mar 23;12:73. doi: 10.1186/1472-6963-12-73.

18.

Effect of i.v. acetaminophen on total hip or knee replacement surgery: a case-matched evaluation of a national patient database.

Apfel C, Jahr JR, Kelly CL, Ang RY, Oderda GM.

Am J Health Syst Pharm. 2015 Nov 15;72(22):1961-8. doi: 10.2146/ajhp140179.

PMID:
26541951
19.

Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling.

Ballal RD, Botteman MF, Foley I, Stephens JM, Wilke CT, Joshi AV.

Curr Med Res Opin. 2008 Mar;24(3):753-68. doi: 10.1185/030079908X273048. Epub 2008 Jan 29.

PMID:
18234151
20.
Items per page

Supplemental Content

Write to the Help Desk